Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non ‐small cell lung cancer: Management of adverse events

ConclusionsThe adherence to lung dose constraints such as V20 as well as close treatment monitoring are a prerequisite for the management of pneumonitis during maintenance therapy with durvalumab.

Source: Thoracic Cancer - March 16, 2020 Category: Cancer & Oncology Authors: Yu Miura, Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Fuyumi Nishihara, Shun Shinomiya, Tomoe Akagami, Yoshitake Murayama, Takanori Abe, Shin ‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu Tags: ORIGINAL ARTICLE Source Type: research